Will Eli Lilly's new weight loss drug Zepbound sell >$2B in the US by 2025? (first full year on the market)
Basic
5
Ṁ1249
Feb 16
99%
chance

This market will resolve to YES if Zepbound has sold at least $2 billion in the US after its first 4 full quarters on the market. The evaluation criteria will be Eli Lilly's Annual Report for FY 2024. This is expected to be available in February 2025.

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

Get
Ṁ1,000
and
S3.00
© Manifold Markets, Inc.Terms + Mana-only TermsPrivacyRules